Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: insights from real-life cases and literature analysis
##plugins.themes.themeTen.article.main##
Keywords
mepolizumab, eosinophilic granulomatosis with polyangiitis, EGPA, interleukin 5-inhibitor, IL5-inhibitor, vasculitis, severe asthma, bologic therapy, mepolizumab real-life efficacy, case series, literature review
Abstract
Background and aim: Recently, the MIRRA trial demonstrated the efficacy and safety of mepolizumab in refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) and the usefulness of this drug as a steroid-sparing agent. However, until now, only a few evidence is available about its effectiveness and safety in clinical practice. In this paper, we report our experience in the treatment of EGPA patients with mepolizumab in a real-world setting and review the current literature on this topic.
Methods: We retrospectively enrolled 14 patients that underwent mepolizumab therapy for EGPA at any dose and with a follow-up of at least 3 months. For each patient, demographic and clinical manifestations of the disease, laboratory parameters, BVAS, asthma exacerbations, and therapeutic management were recorded at the beginning and at the end of mepolizumab therapy.
Results: After a median follow-up of 16 months (3-60), all EGPA patients were in remission for both vasculitis and asthma manifestations. Mepolizumab was associated with a reduction in corticosteroids daily dose, with a significant number of patients able to discontinue corticosteroids (8/14 patients). No patients withdrew mepolizumab and no severe adverse events were recorded.
Conclusion: Our data support the long-term effectiveness of mepolizumab and, in particular, they are suggestive for a good safety profile of this drug among patients with EGPA. In the nearest future, the possibility to obtain a sustained remission in EGPA without the use of steroids should be investigated in larger controlled studies.
References
2. Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013 Mar;68(3):261-73. doi: 10.1111/all.12088.
3. Greco A, Rizzo MI, De Virgilio A, et al. Churg-Strauss syndrome. Autoimmun Rev. 2015 Apr;14(4):341-8. doi: 10.1016/j.autrev.2014.12.004.
4. Fagni F, Bello F, Emmi G. Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology. Front Med (Lausanne). 2021 Feb 24;8:627776. doi: 10.3389/fmed.2021.627776.
5. Fijolek J, Radzikowska E. Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment. Front Med (Lausanne). 2023 May 3;10:1145257. doi: 10.3389/fmed.2023.1145257.
6. Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020 Apr;69(2):178-186. doi: 10.1016/j.alit.2020.02.002.
7. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017;376:1921–32.
8. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–9.
9. Emmi G, Bettiol A, Gelain E, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023 Jun;19(6):378-393. doi: 10.1038/s41584-023-00958-w.
10. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022 Mar;81(3):309-314. doi: 10.1136/annrheumdis-2021-221794.
11. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.
12. Vultaggio A, Nencini F, Bormioli S, et al. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis. Allergy Asthma Immunol Res. 2020 Sep;12(5):885-893. doi: 10.4168/aair.2020.12.5.885.
13. Detoraki A, Tremante E, Poto R, et al. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series. Respir Res. 2021 Jun 23;22(1):185. doi: 10.1186/s12931-021-01775-z.
14. Ueno M, Miyagawa I, Nakano K, et al. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther. 2021 Mar 16;23(1):86. doi: 10.1186/s13075-021-02462-6.
15. Bettiol A, Urban ML, Dagna L, et al. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis Rheumatol. 2022 Feb;74(2):295-306. doi: 10.1002/art.41943.
16. Özdel Öztürk B, Yavuz Z, Aydın Ö, et al. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience. Int Arch Allergy Immunol. 2022;183(12):1281-1290. doi: 10.1159/000526410.
17. Can Bostan O, Duran E, Tuncay G, et al. Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study. J Asthma. 2023 May;60(5):931-937. doi: 10.1080/02770903.2022.2109165.
18. Ishii T, Kunishige H, Kobayashi T, et al. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study. Mod Rheumatol. 2023 Dec 8:road109. doi: 10.1093/mr/road109.
19. Masumoto N, Oshikata C, Nakadegawa R, et al. Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis. Allergy Asthma Clin Immunol. 2023 May 13;19(1):40. doi: 10.1186/s13223-023-00801-7.
20. Toscano Peña A, Ali Munive A, Arevalo Y. Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report. Cureus. 2023 May 9;15(5):e38797. doi: 10.7759/cureus.38797.
21. Portacci A, Campisi R, Buonamico E, et al. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023.
22. Yamane T, Hashiramoto A. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan. Arthritis Res Ther. 2023 Jun 26;25(1):110. doi: 10.1186/s13075-023-03097-5.
23. Jayne DRW, Terrier B, Hellmich B, et al. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics. ERJ Open Res. 2024 Jan 8;10(1):00509-2023. doi: 10.1183/23120541.00509-2023.
24. Fagni F, Bello F, Emmi G. Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology. Front Med (Lausanne). 2021 Feb 24;8:627776. doi: 10.3389/fmed.2021.627776.
25. Emmi, G., Bettiol, A., Gelain, E. et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 2019, 378–393 (2023). doi: 10.1038/s41584-023-00958-w
26. Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019 Nov 12;10(1):5120. doi: 10.1038/s41467-019-12515-9. PMID: 31719529; PMCID: PMC6851141.
27. Terrier B, Jayne DRW, Hellmich B, et al. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype. ACR Open Rheumatol. 2023 Jul;5(7):354-363. doi: 10.1002/acr2.11571.
28. Nakamura Y, Fukutomi Y, Sekiya K, et al. Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis. Mod Rheumatol. 2022 Feb 28;32(2):387-395. doi: 10.1093/mr/roab005.
29. Kai Y, Yoshikawa M, Matsuda M, et al. Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab. Allergy Asthma Clin Immunol. 2022 Feb 19;18(1):14. doi: 10.1186/s13223-022-00653-7.
30. Papo M, Sinico RA, Teixeira V, et al. Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology (Oxford). 2021 Sep 1;60(9):4355-4360. doi: 10.1093/rheumatology/keaa805.
31. Iudici M, Pagnoux C, Courvoisier DS, et al. Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Semin Arthritis Rheum. 2021 Apr;51(2):339-346. doi: 10.1016/j.semarthrit.2021.02.002. Epub 2021 Feb 10.
32. Nguyen Y, Pagnoux C, Karras A, et al. Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. J Autoimmun. 2020 Aug;112:102467. doi: 10.1016/j.jaut.2020.102467.
33. Bahap-Kara M, Sariyildiz E, Zengin HY, Karadag O, Bayraktar-Ekincioglu A. Prospective Assessment of Glucocorticoid Toxicity in Rheumatology Practice: A Focus on the Glucocorticoid Toxicity Index. Rheumatology (Oxford). 2024 May 23:keae288. doi: 10.1093/rheumatology/keae288.
34. Scherbacher PJ, Hellmich B, Feng YS, Löffler C. Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis. RMD Open. 2024 Feb 29;10(1):e003956. doi: 10.1136/rmdopen-2023-003956.
##plugins.themes.themeTen.article.sidebar##
##plugins.themes.themeTen.article.details##
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
